These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 23963361

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.
    Radhakrishnan P, Bryant VC, Blowers EC, Rajule RN, Gautam N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MA, Natarajan A.
    Clin Cancer Res; 2013 Apr 15; 19(8):2025-35. PubMed ID: 23444213
    [Abstract] [Full Text] [Related]

  • 4. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A, Zang C, Chumduri C, Dörken B, Daniel PT, Scholz CW.
    Int J Cancer; 2013 Oct 15; 133(8):1813-24. PubMed ID: 23580240
    [Abstract] [Full Text] [Related]

  • 5. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ.
    Mol Cancer Ther; 2010 Jul 15; 9(7):2026-36. PubMed ID: 20606045
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A, Seong KM, Kang HJ, Park S, Lee SS.
    Oncotarget; 2015 Nov 10; 6(35):38225-38. PubMed ID: 26517678
    [Abstract] [Full Text] [Related]

  • 7. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN.
    Blood; 2015 Sep 24; 126(13):1565-74. PubMed ID: 26254443
    [Abstract] [Full Text] [Related]

  • 8. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.
    Int J Cancer; 2018 Jan 01; 142(1):202-213. PubMed ID: 28905990
    [Abstract] [Full Text] [Related]

  • 9. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 01; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
    Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ.
    J Immunol; 2003 Jul 01; 171(1):88-95. PubMed ID: 12816986
    [Abstract] [Full Text] [Related]

  • 11. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D, Mao C, Zhou Y, Su Y, Liu S, Qi WQ.
    Int J Oncol; 2016 Jan 01; 48(1):253-60. PubMed ID: 26549638
    [Abstract] [Full Text] [Related]

  • 12. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P.
    Mol Cancer; 2014 Jun 27; 13():159. PubMed ID: 24972933
    [Abstract] [Full Text] [Related]

  • 13. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.
    Biochem Pharmacol; 2012 Aug 15; 84(4):451-8. PubMed ID: 22687624
    [Abstract] [Full Text] [Related]

  • 14. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.
    Am J Pathol; 2006 Dec 15; 169(6):2171-80. PubMed ID: 17148679
    [Abstract] [Full Text] [Related]

  • 15. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N.
    Blood; 2012 Mar 15; 119(11):2568-78. PubMed ID: 22294726
    [Abstract] [Full Text] [Related]

  • 16. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, Roué G.
    Clin Cancer Res; 2012 Oct 01; 18(19):5278-89. PubMed ID: 22879389
    [Abstract] [Full Text] [Related]

  • 17. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, Honma D, Adachi N, Araki K, Kato A, Inaki K, Ono Y, Fukuhara S, Kobayashi Y, Tobinai K, Kitabayashi I.
    Cancer Sci; 2021 Jun 01; 112(6):2314-2324. PubMed ID: 33792119
    [Abstract] [Full Text] [Related]

  • 18. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ.
    Blood; 2016 Mar 03; 127(9):1128-37. PubMed ID: 26675347
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
    Yuan J, Zhang Q, Wu S, Yan S, Zhao R, Sun Y, Tian X, Zhou K.
    Exp Hematol; 2021 Nov 03; 103():52-59.e2. PubMed ID: 34474146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.